THC and CBD Suppressed a Key Inflammatory Signal in Human Immune Cells

THC and CBD suppressed IL-1beta production by blocking inflammasome formation and caspase-1 activity in TLR7/TLR8-activated CD16+ monocytes. This occurred at the post-translational level; mRNA expression of IL1B, CASP1, NLRP3, and PYCARD was unaffected. A CB2-selective agonist (JWH-015) did not replicate these effects, indicating the mechanism is not mediated by CB2 receptors alone.

Primary human CD16+ and CD16- monocytes were isolated and pretreated with THC, CBD, or JWH-015, then activated through TLR7 or TLR8 (viral sensing receptors). Inflammasome formation, caspase-1 activity, cytokine secretion, and gene expression were measured.

IL-1beta is a master inflammatory cytokine implicated in conditions from rheumatoid arthritis to HIV-associated neurological disease. Understanding exactly how cannabinoids suppress it at the protein level (not gene level) provides a specific mechanistic target for therapeutic development.

The finding that cannabinoids suppress inflammation through post-translational mechanisms rather than gene regulation is significant because it suggests faster-acting effects. It also explains why CB2 receptor agonists alone fail to replicate the anti-inflammatory profile of whole cannabinoids.

In vitro study using isolated human monocytes outside their tissue context. Concentrations of THC and CBD used may not reflect achievable tissue levels. Single-receptor agonist comparison does not rule out involvement of other receptors. Acute treatment does not capture chronic exposure effects.